122 related articles for article (PubMed ID: 36861107)
1. Addition of a Genetic Risk Score for Identification of Men with a Low Prostate-specific Antigen Level in Midlife at Risk of Developing Lethal Prostate Cancer.
Ma C; Ericsson C; Carlsson SV; Lilja H; Kibel A; Graff RE; Plym A; Giovannucci E; Mucci LA; Preston MA; Penney KL
Eur Urol Open Sci; 2023 Apr; 50():27-30. PubMed ID: 36861107
[TBL] [Abstract][Full Text] [Related]
2. Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men.
Preston MA; Gerke T; Carlsson SV; Signorello L; Sjoberg DD; Markt SC; Kibel AS; Trinh QD; Steinwandel M; Blot W; Vickers AJ; Lilja H; Mucci LA; Wilson KM
Eur Urol; 2019 Mar; 75(3):399-407. PubMed ID: 30237027
[TBL] [Abstract][Full Text] [Related]
3. A "PSA pyramid" for men with initial prostate-specific antigen ≤3 ng/ml: a plea for individualized prostate cancer screening.
Randazzo M; Beatrice J; Huber A; Grobholz R; Manka L; Chun FK; Recker F; Kwiatkowski M
Eur Urol; 2015 Oct; 68(4):591-7. PubMed ID: 24794075
[TBL] [Abstract][Full Text] [Related]
4. Baseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer.
Preston MA; Batista JL; Wilson KM; Carlsson SV; Gerke T; Sjoberg DD; Dahl DM; Sesso HD; Feldman AS; Gann PH; Kibel AS; Vickers AJ; Mucci LA
J Clin Oncol; 2016 Aug; 34(23):2705-11. PubMed ID: 27298404
[TBL] [Abstract][Full Text] [Related]
5. Risk-adjusted Screening for Prostate Cancer-Defining the Low-risk Group by Data from the PROBASE Trial.
Krilaviciute A; Kaaks R; Seibold P; de Vrieze M; Lakes J; Radtke JP; Kuczyk M; Harke NN; Debus J; Fink CA; Herkommer K; Gschwend JE; Meissner VH; Benner A; Kristiansen G; Hadaschik B; Arsov C; Schimmöller L; Antoch G; Giesel FL; Makowski M; Wacker F; Schlemmer HP; Becker N; Albers P
Eur Urol; 2024 May; ():. PubMed ID: 38749854
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific antigen and long-term prediction of prostate cancer incidence and mortality in the general population.
Orsted DD; Nordestgaard BG; Jensen GB; Schnohr P; Bojesen SE
Eur Urol; 2012 May; 61(5):865-74. PubMed ID: 22104593
[TBL] [Abstract][Full Text] [Related]
7. Prostate cancer incidence in men with prostate-specific antigen below 3 ng/mL: The Finnish Randomized Study of Screening for Prostate Cancer.
Ola IO; Talala K; Tammela T; Taari K; Murtola T; Kujala P; Raitanen J; Auvinen A
Int J Cancer; 2023 Feb; 152(4):672-678. PubMed ID: 36056577
[TBL] [Abstract][Full Text] [Related]
8. The Combined Effect of Polygenic Risk Score and Prostate Health Index in Chinese Men Undergoing Prostate Biopsy.
Ruan X; Huang D; Huang J; Huang J; Zhan Y; Wu Y; Ding Q; Xu D; Jiang H; Xue W; Na R
J Clin Med; 2023 Feb; 12(4):. PubMed ID: 36835879
[TBL] [Abstract][Full Text] [Related]
9. A genetic score can identify men at high risk for prostate cancer among men with prostate-specific antigen of 1-3 ng/ml.
Nordström T; Aly M; Eklund M; Egevad L; Grönberg H
Eur Urol; 2014 Jun; 65(6):1184-90. PubMed ID: 23891454
[TBL] [Abstract][Full Text] [Related]
10. Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening.
Assel M; Dahlin A; Ulmert D; Bergh A; Stattin P; Lilja H; Vickers AJ
Eur Urol; 2018 Jun; 73(6):961-967. PubMed ID: 29066048
[TBL] [Abstract][Full Text] [Related]
11. Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy.
Brockman JA; Alanee S; Vickers AJ; Scardino PT; Wood DP; Kibel AS; Lin DW; Bianco FJ; Rabah DM; Klein EA; Ciezki JP; Gao T; Kattan MW; Stephenson AJ
Eur Urol; 2015 Jun; 67(6):1160-1167. PubMed ID: 25301759
[TBL] [Abstract][Full Text] [Related]
12. Prostate cancer polygenic risk score and prediction of lethal prostate cancer.
Klein RJ; Vertosick E; Sjoberg D; Ulmert D; Rönn AC; Häggström C; Thysell E; Hallmans G; Dahlin A; Stattin P; Melander O; Vickers A; Lilja H
NPJ Precis Oncol; 2022 Apr; 6(1):25. PubMed ID: 35396534
[TBL] [Abstract][Full Text] [Related]
13. Baseline Serum Prostate-specific Antigen Value Predicts the Risk of Subsequent Prostate Cancer Death-Results from the Norwegian Prostate Cancer Consortium.
Bjerner J; Bratt O; Aas K; Albertsen PC; Fosså SD; Kvåle R; Lilja H; Müller C; Müller S; Stensvold A; Thomas O; Røe OD; Vickers A; Walz J; Carlsson SV; Oldenburg J
Eur Urol; 2023 May; ():. PubMed ID: 37169639
[TBL] [Abstract][Full Text] [Related]
14. Genetic risk assessment of lethal prostate cancer using polygenic risk score and hereditary cancer susceptibility genes.
Ruan X; Huang D; Huang J; Tsu JH; Na R
J Transl Med; 2023 Jul; 21(1):446. PubMed ID: 37415201
[TBL] [Abstract][Full Text] [Related]
15. Evidence of Novel Susceptibility Variants for Prostate Cancer and a Multiancestry Polygenic Risk Score Associated with Aggressive Disease in Men of African Ancestry.
Chen F; Madduri RK; Rodriguez AA; Darst BF; Chou A; Sheng X; Wang A; Shen J; Saunders EJ; Rhie SK; Bensen JT; Ingles SA; Kittles RA; Strom SS; Rybicki BA; Nemesure B; Isaacs WB; Stanford JL; Zheng W; Sanderson M; John EM; Park JY; Xu J; Wang Y; Berndt SI; Huff CD; Yeboah ED; Tettey Y; Lachance J; Tang W; Rentsch CT; Cho K; Mcmahon BH; Biritwum RB; Adjei AA; Tay E; Truelove A; Niwa S; Sellers TA; Yamoah K; Murphy AB; Crawford DC; Patel AV; Bush WS; Aldrich MC; Cussenot O; Petrovics G; Cullen J; Neslund-Dudas CM; Stern MC; Kote-Jarai Z; Govindasami K; Cook MB; Chokkalingam AP; Hsing AW; Goodman PJ; Hoffmann TJ; Drake BF; Hu JJ; Keaton JM; Hellwege JN; Clark PE; Jalloh M; Gueye SM; Niang L; Ogunbiyi O; Idowu MO; Popoola O; Adebiyi AO; Aisuodionoe-Shadrach OI; Ajibola HO; Jamda MA; Oluwole OP; Nwegbu M; Adusei B; Mante S; Darkwa-Abrahams A; Mensah JE; Diop H; Van Den Eeden SK; Blanchet P; Fowke JH; Casey G; Hennis AJ; Lubwama A; Thompson IM; Leach R; Easton DF; Preuss MH; Loos RJ; Gundell SM; Wan P; Mohler JL; Fontham ET; Smith GJ; Taylor JA; Srivastava S; Eeles RA; Carpten JD; Kibel AS; Multigner L; Parent MÉ; Menegaux F; Cancel-Tassin G; Klein EA; Andrews C; Rebbeck TR; Brureau L; Ambs S; Edwards TL; Watya S; Chanock SJ; Witte JS; Blot WJ; Michael Gaziano J; Justice AC; Conti DV; Haiman CA
Eur Urol; 2023 Jul; 84(1):13-21. PubMed ID: 36872133
[TBL] [Abstract][Full Text] [Related]
16. A Calculator for Prostate Cancer Risk 4 Years After an Initially Negative Screen: Findings from ERSPC Rotterdam.
Roobol MJ; Zhu X; Schröder FH; van Leenders GJ; van Schaik RH; Bangma CH; Steyerberg EW
Eur Urol; 2013 Apr; 63(4):627-33. PubMed ID: 22841675
[TBL] [Abstract][Full Text] [Related]
17. Long-term prostate-specific antigen velocity in improved classification of prostate cancer risk and mortality.
Ørsted DD; Bojesen SE; Kamstrup PR; Nordestgaard BG
Eur Urol; 2013 Sep; 64(3):384-93. PubMed ID: 23398767
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of men with an elevated prostate-specific antigen (PSA) level as their sole preoperative intermediate- or high-risk feature.
Faisal FA; Sundi D; Pierorazio PM; Ball MW; Humphreys EB; Han M; Epstein JI; Partin AW; Carter HB; Bivalacqua TJ; Schaeffer EM; Ross AE
BJU Int; 2014 Dec; 114(6b):E120-E129. PubMed ID: 24731026
[TBL] [Abstract][Full Text] [Related]
19. Clinical Utility of Germline Genetic Testing in Japanese Men Undergoing Prostate Biopsy.
Akamatsu S; Terada N; Takata R; Kinoshita H; Shimatani K; Momozawa Y; Yamamoto M; Tada H; Kawamorita N; Narita S; Kato T; Nitta M; Kandori S; Koike Y; Inazawa J; Kimura T; Kimura H; Kojima T; Terachi T; Sugimoto M; Habuchi T; Arai Y; Yamamoto S; Matsuda T; Obara W; Kamoto T; Inoue T; Nakagawa H; Ogawa O
JNCI Cancer Spectr; 2022 Feb; 6(1):. PubMed ID: 35118230
[TBL] [Abstract][Full Text] [Related]
20. Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events trial.
Muller RL; Gerber L; Moreira DM; Andriole G; Castro-Santamaria R; Freedland SJ
Eur Urol; 2012 Nov; 62(5):757-64. PubMed ID: 22658758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
